Health Care

Regeneron’s gene‑therapy REG‑HL1 earns FDA accelerated approval, offering free treatment for rare congenital hearing loss and setting a new standard for equitable, outcome‑based pricing in gene‑therapy development.

Edwards Lifesciences Q1 2026 earnings show modest EPS growth and a 7.3 % revenue rise driven by valve sales and a critical‑care rebound.

Medtronic’s Affera™ portfolio, highlighted by Sphere‑9’s breakthrough data and strategic acquisitions, promises faster approvals, higher success rates, and a stronger future in cardiac tech.

Thermo Fisher Scientific reports Q1 2026 earnings: $3.15 EPS, 2% revenue rise, and 10% net profit increase, driven by high‑margin life‑science tools and expanding drug‑development partnerships.

Explore Sartorius AG’s Q1 2026 results: modest revenue rise, strong EPS growth, and robust bioprocess and lab‑instrument performance—key insights for investors and pharma stakeholders.

Novo Nordisk shares rise as new oral semaglutide data show equal efficacy to injections, with Medicare GLP‑1 Bridge program and price cuts boosting patient access and adherence.

FMC’s new partnership with Humacyte to distribute Sym vess in Europe offers low‑cost, high‑margin entry into regenerative vascular repair, diversifying its dialysis‑heavy portfolio and boosting future earnings potential.

Danaher’s EPS surprise, bioprocessing rebound, and $10 B Masimo takeover show a pivot to integrated life‑science solutions—boosting orders, consumables, and diagnostic reach.

Regeneron’s FDA‑approved gene therapy Otarmeni offers a curative, no‑cost solution for rare otoferlin‑related hearing loss, backed by strong revenue potential and value‑based pricing.

Haleon PLC climbs amid mixed European markets, showing resilience as pharma & consumer‑health sectors navigate geopolitical uncertainty and supply‑chain challenges.